Increasing Public Awareness and Provider Education about Primary Immunodeficiency Disease

 

The purpose of the program is to strengthen the nation?s capacity to carry out public health activities in the area of primary immunodeficiency diseases (PID) by increasing and improving physician education and public health awareness for/of PID. The intent is to disseminate educational information on a national level to health care providers, educators, third-party payers, impacted families, and others who may help expedite clinical recognition and improve health outcomes for Americans with primary immunodeficiency diseases.

Active 93.980 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants; Z - Salaries and Expenses Not applicable. Public Health Service Act, 42 USC 247 b (K)(2), 12372 This FOA will be full and open competition. The ideal applicant will have ten years of experience in: conducting effective physician education and public awareness campaigns for primary immunodeficiency diseases, collaborating effectively with health care and public health partners, and maximizing resources dedicated to campaign materials development and distribution to meet outcome goals. The general public will benefit from outcome of this FOA. The ideal applicant will have ten years of experience in: conducting effective physician education and public awareness campaigns for primary immunodeficiency diseases, collaborating effectively with health care and public health partners, and maximizing resources dedicated to campaign materials development and distribution to meet outcome goals. Applicants are required to include all required documents with their application package at www.grantsolutions.gov. .Costs will be determined in accordance with OMB Circular No A-87 for State and Local governments. For all non-profit grantees, costs will be determined in accordance with the Federal Acquisition Regulations, 48 CFR 31. OMB Circular No. A-87 applies to this program, 2 CRF 200, Subpart E-Cost Principles applies to this program. Preapplication coordination is required. N/A 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. To apply for this funding opportunity, use guidance listed in the announcement. If you do not have internet, of you have difficulty accessing the forms online, you may contact CDC Office of Grants Services at 770-488-2700. Applications will be evaluated for completeness and responsiveness by the agency program and CDC Office of Grant Services (OGS). CDC will not review incomplete and non-responsive applications. After review and approval, a notice of grant award (NoA) will be prepared and processed, along with appropriate notification July 20, 2017 to July 19, 2022 From 90 to 120 days. Not applicable. The grant project period is 1 to 5 years. Subject to availability of funds after initial award. Projects may be renewed non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the federal government. Applicants will be evaluated on the review criteria described in the funding Opportunity Announcement (FOA). In general, the review and selection process of complete and responsive applications to the FOA consists of determination of the scientific and technical merit by objective review panel, availability of funds, and relevance of program priorities and the priorities of DHHS. Refer to the FOA for additional review criteria. The budget is not scored. Grants funds will not be used for research activities. Funding for this grant will be used to reduce the burden of primary immunodeficiency diseases. Funding for activities should be allocated per the strategy to best meet the short, medium, and long term outcome goals. Performance Reports: Interim reports from each entity award summarizing the activities undertaken and identifying any sub-grants or sub-contracts awarded to be posted no later than 30 days after the end of each 6-month period. Congress directed HHS to provide information on activities and programs supported by federal funds. No cash reports are required. Federal financial reports are required 90 days after the e end of the project period. Consult with CDC about performance monitoring activities. Consult with CDC about performance monitoring requirements. In accordance with the provisions of 2 CFR 200, Subpart F-Audit requirements, non-federal entities that expend financial assistance of $750,0000 or more I federal awards will have a single or program specific audited conducted for that year. Non-federal entities that expend less than $750,000 a year in Federal funds are exempt from Federal audit requirements for that year except as n noted in 2 CFR 200.503. Consult with CDC Office of Grant Services for information. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with project periods of up to five years subject to the availability of funds and satisfactory progress of the grantee. See FOA announcement for information on how assistance is awarded/released. Grantee should consult OGS for additional information. Grantee should consult CDC Office of Grant Services for additional information. None/Not specified. Scott Bowen
1600 Clifton Road
Altanta, GA 30329 US
sbowen1@cdc.gov
Phone: 404-498-0068
Fax: 404-498-0140 http://WWW.CDC.GOV 75-0959-0-1-550 (Salaries and Expenses) FY 18$921,500.00; FY 19 est $1,848,000.00; FY 20 est $921,500.00; FY 17$921,500.00; FY 16 Estimate Not Available - FY 2017 Estimated at 921, 500 FY2018 Estimated at 921, 500 FY2019 Estimated at 921, 500 FY2020 Estimated at 921, 500 FY2021 Estimated at 921, 500 Total anticipated funding is $4,607,500. Future funding is subject to availability of funds. FY 2017 Estimated at 921, 500 FY2018 Estimated at 921, 500 FY2019 Estimated at 921, 500 FY2020 Estimated at 921, 500 FY2021 Estimated at 921, 500 Total anticipated funding is $4,607,500. Future funding is subject to availability of funds. Not applicable. Not applicable.